Long-term body composition changes in antiretroviral-treated HIV-infected individuals

AIDS

Volumn 30, Issue 18, 2016, Pages 2805-2813

  Grant, Philip M ^a   Kitch, Douglas ^b   McComsey, Grace A ^c   Collier, Ann C ^d   Bartali, Benedetta ^e   Koletar, Susan L ^f   Erlandson, Kristine M ^g   Lake, Jordan E ^h   Yin, Michael T ⁱ   Melbourne, Kathy ^j   Ha, Belinda ^k   Brown, Todd T ^l  

^a STANFORD UNIVERSITY   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e NEW ENGLAND RESEARCH INSTITUTES   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ Howard Hughes Medical Institute   (United States)

^j GILEAD SCIENCES   (United States)

^k VIIV HEALTHCARE   (United States)

^l JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Administration dosage; Adverse effects; Anti HIV agents; Body fat distribution; Chemically induced; Drug therapy virology; HIV infection; HIV infections; HIVassociated lipodystrophy syndrome; Humans

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; CD4 ANTIGEN; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;

ADULT; ARTICLE; BODY COMPOSITION; BODY FAT; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LEAN BODY WEIGHT; LIMB; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBESITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; TRUNK; DRUG EFFECTS; FOLLOW UP; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIDDLE AGED; PATHOLOGY; PHOTON ABSORPTIOMETRY; YOUNG ADULT;

ABSORPTIOMETRY, PHOTON; ADULT; ANTI-RETROVIRAL AGENTS; BODY COMPOSITION; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84988644056     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000001248     Document Type: Article

References (24)

1. Erlandson KM, Li X, Abraham AG, Margolick JB, Lake JE, Palella FJ Jr, et al. Long-term impact of HIV wasting on physical function. AIDS 2016; 30:445-454.
2. Scherzer R, Heymsfield SB, Lee D, Powderly WG, Tien PC, Bacchetti P, et al. Decreased limb muscle and increased central adiposity are associated with 5-year all-cause mortality in HIV infection. AIDS 2011; 25:1405-1414.
3. Kooij KW, Wit FW, Schouten J, van der Valk M, Godfried MH, Stolte IG, et al. HIV infection is independently associated with frailty inmiddle-aged HIV type 1-infected individuals compared with similar but uninfected controls. AIDS 2016; 30:241-250.
4. Desquilbet L, Jacobson LP, Fried LP, Phair JP, Jamieson BD, Holloway M, et al. HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty. J Gerontol A Biol Sci Med Sci 2007; 62:1279-1286.
5. Erlandson KM, Allshouse AA, Jankowski CM, MaWhinney S, Kohrt WM, Campbell TB. Functional impairment is associated with low bone and muscle mass among persons aging with HIV infection. J Acquir Immune Defic Syndr 2013; 63:209-215.
6. Shah K, Hilton TN, Myers L, Pinto JF, Luque AE, Hall WJ. A new frailty syndrome: central obesity and frailty in older adults with the human immunodeficiency virus. J Am Geriatr Soc 2012; 60:545-549.
7. McComsey GA, Moser C, Currier J, Ribaudo HJ, Paczuski P, Dubé MP, et al. Body composition changes after initiation of raltegravir or protease inhibitors: ACTG A5260s. Clin Infect Dis 2016; 62:853-862.
8. Haubrich RH, Riddler SA, DiRienzo AG, Komarow L, Powderly WG, Klingman K, et al.Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 2009; 23:1109-1118.
9. McComsey GA, Kitch D, Sax PE, Tebas P, Tierney C, Jahed NC, et al. Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s. Clin Infect Dis 2011; 53:185-196.
10. Martinez E, Mocroft A, García-Viejo MA, Pérez-Cuevas JB, Blanco JL, Mallolas J, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: A prospective cohort study. Lancet 2001; 357:592-598.
11. Reynes J, Trinh R, Pulido F, Soto-Malave R, Gathe J, Qaqish R, et al. Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naïve subjects: 96-week results of the PROGRESS study. AIDS ResHumRetroviruses 2013; 29:256-265.
12. Sax PE, Tierney C, Collier AC, Daar ES, Mollan K, Budhathoki C, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis 2011; 204:1191-1201.
13. Grant PM, Kitch D, McComsey GA, Collier AC, Koletar SL, Erlandson KM, et al. Long-term bone mineral density changes in antiretroviral-treated HIV-infected individuals. J Infect Dis 2016; 214:607-611.
14. Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 2003; 35:1381-1395.
15. Araujo AB, Yang M, Suarez EA, Dagincourt N, Abraham JR, Chiu G, et al. Racial/ethnic and socioeconomic differences in bone loss among men. J Bone Miner Res 2014; 29:2552-2560.
16. Sharma A, Tian F, Yin MT, Keller MJ, Cohen M, Tien PC. Association of regional body composition with bone mineral density in HIV-infected and HIV-uninfected women: women's interagency HIV study. J Acquir Immune Defic Syndr 2012; 61:469-476.
17. Li C, Ford ES, Zhao G, Balluz LS, Giles WH. Estimates of body composition with dual-energy X-ray absorptiometry in adults. Am J Clin Nutr 2009; 90:1457-1465.
18. Yarasheski KE, Scherzer R, Kotler DP, Dobs AS, Tien PC, Lewis CE, et al. Age-related skeletal muscle decline is similar in HIVinfected and uninfected individuals. J Gerontol A Biol Sci Med Sci 2011; 66:332-340.
19. Grunfeld C, Saag M, Cofrancesco J Jr, Lewis CE, Kronmal R, Heymsfield S, et al. Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy. AIDS 2010; 24:1717-1726.
20. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients: A 3-year randomized trial. JAMA 2004; 292:191-201.
21. Tien PC, Schneider MF, Cole SR, Justman JE, French AL, Young M, et al. Relation of stavudine discontinuation to anthropometric changes among HIV-infected women. J Acquir Immune Defic Syndr 2007; 44:43-48.
22. PrayGod G, Blevins M, Woodd S, Rehman AM, Jeremiah K, Friis H, et al. A longitudinal study of systemic inflammation and recovery of lean body mass among malnourished HIV-infected adults starting antiretroviral therapy in Tanzania and Zambia. Eur J Clin Nutr 2016; 70:499-504.
23. Reingold J, Wanke C, Kotler D, Lewis C, Tracy R, Heymsfield S, et al. Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: The fat redistribution and metabolic change in HIV infection (FRAM) study. J Acquir Immune Defic Syndr 2008; 48:142-148.
24. Jackson AS, Janssen I, Sui X, Church TS, Blair SN. Longitudinal changes in body composition associated with healthy ageing: men, aged 20-96 years. Br J Nutr 2012; 107: 1085-1091.